ADXN News

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Addex Convenes Annual General Meeting 2026

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update